Core Viewpoint - The company announced the initiation of a Phase II clinical trial for its core product, Tinengotinib (TT-00420), in combination with other therapies for the treatment of advanced hepatocellular carcinoma (HCC) [1] Group 1: Clinical Trial Details - The trial is an open-label, multicenter Phase II study conducted in China [1] - The primary objective is to evaluate the safety and efficacy of Tinengotinib in combination with Kanfar Biotech's Katanib (PD-1/CTLA-4) and Yida Pharma's Yivofisi (PD-1/VEGF) [1] - The target population includes patients with advanced HCC who have not previously received systemic anti-tumor therapy or have failed standard treatment [1] Group 2: Collaboration and Development - The company has entered into a collaboration agreement with Kanfar Biotech to jointly develop clinical combination therapies in the field of hepatocellular carcinoma [1]
药捷安康-B：替恩戈替尼联用康方生物开坦尼 (卡度尼利，PD-1/CTLA-4)╱ 依达方 (依沃西，PD-1/VEGF)的II期临床试验完成首例患者给药